Fortress Biotech Reports Record First Quarter 2020 Financial Results and Recent Corporate Highlights May 11, 2020
Mustang Bio Reports First Quarter 2020 Financial Results and Recent Corporate Highlights May 11, 2020
Avenue Therapeutics Reports First Quarter 2020 Financial Results and Recent Corporate Highlights May 11, 2020
Fortress Biotech Announces Exclusive Worldwide License Agreement With Columbia University to Develop Novel Oligonucleotide Platform for the Treatment of Genetically Driven Cancers May 08, 2020
Checkpoint Therapeutics Reports First Quarter 2020 Financial Results and Recent Corporate Highlights May 06, 2020
Checkpoint Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Anti-PD-L1 Antibody Cosibelimab Apr 21, 2020
Mustang Bio Receives Advanced Therapy Medicinal Product Classification from European Medicines Agency for MB-107 Lentiviral Gene Therapy for X-Linked Severe Combined Immunodeficiency Apr 20, 2020
Avenue Therapeutics Reports Full Year 2019 Financial Results and Recent Corporate Highlights Mar 30, 2020
Fortress Biotech Announces Up to $5 Million Series A Cumulative Redeemable Perpetual Preferred Stock Repurchase Program Mar 23, 2020
